Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer

The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouzayed, Ayman, Tano, Hanna, Nagy, Ábel, Rinne, Sara S., Wadeea, Fadya, Kumar, Sharmishtaa, Westerlund, Kristina, Tolmachev, Vladimir, Eriksson Karlström, Amelie, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594083/
https://www.ncbi.nlm.nih.gov/pubmed/33081166
http://dx.doi.org/10.3390/pharmaceutics12100977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594083/
https://www.ncbi.nlm.nih.gov/pubmed/33081166
http://dx.doi.org/10.3390/pharmaceutics12100977

Ejemplares similares